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Somatic CLL mutations occur at multiple distinct
hematopoietic maturation stages: documentation and
cautionary note regarding cell fraction purity
Leukemia (2018) 32, 1040–1043; doi:10.1038/leu.2017.343
Since malignancies develop by serial acquisition of somatic
mutations over years or decades,1 cells transitioning from normalcy
to malignancy need a sufﬁciently long life span to accumulate the
required mutations. For cancers of the hematopoietic system, these
cells can be self-renewing hematopoietic stem cells (HSCs) or
cancer-initiating cells that pass genetic alterations down to their
progeny during cell division and differentiation.
Chronic lymphocytic leukemia (CLL), the most common adult
leukemia among Caucasians, results from expansion of clonal
CD5+ B lymphocytes with a mature phenotype growing in bone
marrow (BM), blood and lymph nodes.2 Consistent with stepwise
disease development,3,4 CLL is preceded by a pre-leukemic state,
monoclonal B-lymphocytosis.5,6 Although a series of genomic
abnormalities has been deﬁned in CLL, there is no single lesion or
combination of genetic lesions common to every patient.7
Xenotransplantation studies suggest HSCs isolated from CLL
patients are biased to developing mono-/oligo-clonal B cells with
a CLL-like phenotype, thereby implicating HSCs in disease
development.8 Supporting this implication is the report of
mutations in immature hematopoietic cells (CD34+CD19−) in the
blood of CLL patients.9 Here, we investigated this issue further by
probing the presence of somatic mutations in deﬁned immature
cell populations of the hematopoietic lineage (Supplementary
Figure 1). These populations were isolated by FACS from
granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood (MPB) of CLL patients in remission for whom
autologous stem cell transplantation was anticipated but not
carried out (Supplementary Table 1).
First, using the strategy indicated in Supplementary Figure 2, we
puriﬁed CD5+CD19+ cells from six patients and then identiﬁed
somatic mutations speciﬁc to each leukemic clone by performing
whole-exome sequencing (WES) of CLL cells (mean read depth:
107.5) and paired buccal cells (mean read depth: 61.5). This
revealed a total of 87 coding mutations, with an average of 14.5
(range 7–21) variants per sample (Supplementary Tables 2 and 3), in
line with previous reports.10 In three additional cases for which
matched normal DNA was not available (mean read depth: 91.8),
mutation calls were limited to known CLL driver genes,7 accounting
for a total of 95 substitutions and small indels (Supplementary

Table 3). The sequences reported in this paper have been deposited
in the NCBI's BioProject database under project PRJNA411889.
Next, we assessed the sensitivity for detecting small, subclonal
mutations using amplicon-based deep sequencing, the approach
we would subsequently use to identify the above mutations in
immature hematopoietic cells from the patients. Detection sensitivity was determined using serial dilutions of a cell line harboring a
known heterozygous TP53 mutation (Supplementary Methods). This
indicated that a sequencing depth of 20 000 × to 100 000 × was
sufﬁcient to detect 41 mutated alleles out of 10 000 wild-type
alleles, against background sequencing errors (Supplementary
Figure 3). Increasing sequencing depth to 1 000 000 × did not
improve sensitivity, as sequencing errors occurred at rates similar to
those of true somatic mutations (Supplementary Figure 3).
Next from the nine CLL patients’ G-CSF MPB, we isolated by
FACS the following fractions: HSC plus MPP (Multi-Potent
Progenitor
cell)
(HSC+MPP),
deﬁned
as
Lin−CD34+
CD38lowCD45RA−CD90+/CD90−; downstream Hematopoietic Progenitor Cell populations (HPC) containing Common Lymphoid
Progenitors and Common Myeloid Progenitors, marked as Lin−
CD34+CD38+; and mature T cells (CD3+CD19−) and monocytes (
CD14+CD19−) (Supplementary Figure 2). Post-sorting, the average
purity of the HSC+MPP fractions was ⩾ 99%. Nevertheless, to
evaluate contamination of the cell fractions with mature CLL B
cells, we searched for tumor-speciﬁc immunoglobulin VH CDR3
sequences by employing a qPCR protocol that is used to detect
minimal residual disease (MRD) in patients with leukemia,11
achieving a sensitivity of ⩽ 10− 4 (7 patients), ⩽ 10 − 5 (1 patient),
and 5 × 10 − 4 (1 patient) (Supplementary Table 4). Out of a total of
32 populations analyzed, 9 were ‘pure’, that is, below the level of
detection of the patient-speciﬁc VH CDR3 sequences; these
included 4/8 HSC+MPP, 3/9 HPC Population initially indicated as
HPC, 1/8 CD3+CD19 − and 1/6 CD14+CD19− (Figure 1a). In the
remaining 23 fractions, contamination with mature CLL cells was
found at various levels, ranging from low (between 5 × 10 − 5 and
5 × 10 − 4; n = 13) to higher (45 × 10 − 4; n = 10) grade contamination (Supplementary Table 4).
Having measured the levels of contaminating CLL cells and the
sequencing sensitivity, we performed multiplex deep sequencing
targeting 92 unique loci in patient-matched immature and mature
hematopoietic populations; this interrogated 91% of the mutations (n = 86/95) previously identiﬁed in the corresponding CLL
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Figure 1. Fractions within the hematopoietic differentiation pathway containing somatic mutations in CLL patients. (a) Cell fractions free of
mature CLL-cell contamination as assessed by patient-speciﬁc VH CDR3 qPCR. Nine fractions were scored as ‘pure’ based on the inability to
detect patient-speciﬁc VH CDR3 signatures by qPCR. In the remaining 23 fractions (not shown here, see Supplementary Table 4), mature CLL cell
VH CDR3 signatures were found at various levels indicating low-grade (5 × 10 − 5 − 5 × 10 − 4; n = 13) to higher-grade (45 × 10 − 4; n = 10)
contamination. Speciﬁc mutations are listed in those pure fractions in which they were found. The contaminated fractions are highlighted in
gray. NA: sample not available. (b) Assignment of somatic genomic changes to the earliest cells in the hematopoietic lineage (HSC+MPP of CLL2
SF3B1-K700E) or to cells at or downstream of the CMP/CLP stages (CLL8 and CLL6). Assignments restricted to those fractions noted in A as ‘pure’.
For CLL 2, initial mutation occurred in the HSC+MPP fraction. Whereas in CLL 8, all mutations occurred within the B-cell lineage (between pro-B
and mature B-cell stages), since the patient’s companion T cells did not contain the same mutation. For CLL6, the precise relationship cannot be
deﬁned because the companion T-cell population was contaminated with mature CLL B cells. Hence, the mutation for CLL6 occurred
downstream of the combined CMP/CLP stage, possibly just upstream of the T- and B-cell bifurcation or within the B-cell lineage; this
equivocation is indicated by the dotted line. For CLL5 and CLL11, more than one mutation was detected in the indicated fraction (see panel a).

dominant clone (Supplementary Table 5). The contaminated
populations were also included as controls in the deep sequencing experiment. This approach yielded an average of 56 572 pairs
of reads per sample per locus (range: 289–182 851). We then
developed a Bayesian approach to assess the presence of true
mutations at very low abundance. Each mutation was tested
against 18 negative control samples from HSC+MPP and HPC,
isolated from G-CSF MPB of nine healthy adult donors (40–57
years of age) who underwent stem cell mobilization as donors for
allogeneic transplantation. Sequencing DNA from the same
immature cell fractions of normal individuals at identical genomic
regions and at the same depth provided a true assessment of the
error rate at a given position. This indicated signiﬁcant mutationdependent variation in sensitivity. Speciﬁcally, when the sequencing error rate for a given nucleotide change was low (for
example, as for transversions), we could discern mutations present
at ⩾ 1 in 10 000 alleles (Supplementary Figure 3). In contrast, for
variants associated with a high sequencing error rate (for
© 2018 Macmillan Publishers Limited, part of Springer Nature.

transitions), the sensitivity was reduced to 5–10 in 10 000 alleles,
independent of sequencing depth. As expected, targeted deep
sequencing of ‘tumor contaminated’ samples identiﬁed all events
detected by WES in the CLL clone (not shown), documenting the
sensitivity and accuracy of the approach.
Focusing on the contamination-free cell fractions (ﬁve patients;
Figure 1a), several observations emerged. First, for CLL6 and CLL8,
none of the WES-identiﬁed mutations could be found in the HSC
+MPP and HPC fractions, and for CLL8 also not in the CD3+ and
CD14+ fractions (Figure 1). These ﬁndings suggest that, for both
patients, the genetic point variants found in the mature CLL cells
occurred downstream of Common Lymphoid and Common
Myeloid Progenitors (HPC Population initially indicated as HPC),
and, for CLL8, after the bifurcation between T and B lymphocytes,
that is, cells committed to the B-cell lineage (Figure 1b).
Second, although we did not detect the SF3B1-I704F
mutation (sensitivity 40.01%) that had been observed by
WES in the leukemic B cells of CLL2 (variant allele frequency,
Leukemia (2018) 1034 – 1051
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Figure 2. SF3B1-K700E mutation occurs in CLL2 HSC+MPP fraction, whereas SF3B1-I704F mutation is only detected further down in the
hematopoietic differentiation pathway. (a) Detection of SF3B1-K700E in CLL2 HSC+MPP fraction. Although SF3B1-I704F was present in mature
CLL2 B cells, deep sequencing analysis did not detect this mutation in the HSC+MPP population of CLL2, or in the control undiluted and 1:103
diluted mature CLL4 B-cells (VAF o0.01%). However, SF3B1-K700E was identiﬁed in both CLL2 HSC+MPP and in the companion mature B cells
(VAF 40.15%), as well as in undiluted and 1:103 diluted mature CLL4 B-cells at expected VAFs. (b) Graphical representation for the pattern of
SF3B1 mutations identiﬁed in CLL2 by targeted sequencing at 4630 000 depth. SF3B1-I704F was identiﬁed with a VAF of 47% by WES in the
leukemic clone but was not found in the HSC+MPP fraction (VAF o0.01%). SF3B1-K700E mutation was present in the HSC +MPP fraction (VAF
40.15%), and the same abundance was maintained in the mature CLL B-cell clone (VAF 40.15%).

VAF = 47%) (Figure 2), we did ﬁnd an SF3B1-K700E mutation
(VAF 40.15%) in the HSC+MPP fraction, which had not been
identiﬁed by WES (Supplementary Table 3). Therefore, we
repeated the deep sequencing experiment at 10-fold
increased depth, testing undiluted mature CLL2 cells as well
as undiluted and 1:10 3 diluted mature CLL4 cells as positive
controls (since they harbored the SF3B1-K700E mutation,
VAF = 37%). This approach conﬁrmed the SF3B1-K700E mutation (VAF 40.15%) and the absence of the SF3B1-I704F
mutation (Figure 2; Supplementary Table 6) in the HSC+MPP
fraction of CLL2. Interestingly, the SF3B1-K700E mutation was
also detected in mature CLL2 cells (VAF 40.15%). Examining
individual reads for these mutations indicated that SF3B1K700E existed in clones mutually exclusive from those
harboring
SF3B1-I704F
(chi-squared
test
P o 0.0001;
Supplementary Methods). This points out the high mutability
and signiﬁcance of this gene in CLL development, and is
consistent with growth/survival advantages of subclones that
acquire more mutations to become dominant populations. The
presence of mutually exclusive clones with low-frequency
SF3B1 mutations in newly diagnosed CLL has been reported.12
Finally, in the HSC+MPP of CLL5 and HPC of CLL11a, deep
sequencing detected 50% and 82% of the mutations identiﬁed by
WES in the mature CLL cells, respectively (Figure 1a,
Supplementary Table 7). These ﬁndings raise the concern of
tumor contamination below the sensitivity of the VH CDR3
analysis but discernible by our sequencing approach. Indeed,
Leukemia (2018) 1034 – 1051

deep sequencing of CLL11a HPC Population initially indicated as
HPC detected 61% of the mutations identiﬁed by WES in a sample
of non-mobilized PB obtained 4 years later (‘CLL11b’). Speciﬁcally,
88% of mutations shared by CLL11a and CLL11b, and 40% of
mutations speciﬁc to CLL11b were found in the HPCs.
In summary, our ﬁndings conﬁrm that CLL mutations can occur
in CD34+ cells9 and precisely deﬁne HSC+MPP and HPC as the
fractions containing these mutations. In addition, our results
indicate that not all CLL clones develop mutations at these
maturation stages. Although we cannot discount that mutations
are acquired in non-coding genomic regions, of the four tumor
samples with pure HPC+MPP fractions (Figure 1a), only one had a
CLL exome mutation (25%). For two cases, none of the CLL
mutations were found in these cell populations, and for a third all
variants had to develop after commitment to the B-cell lineage
(Figures 1a and b). Moreover, despite starting with more CD34enriched samples (G-CSF MPB) than others9 and achieving
499% pure precursor populations by FACS, several fractions
contained mature CLL-cell ‘contaminants’ that were detected by
high sensitivity, ultra-deep sequencing and MRD methods.
Indeed, only ~ 28% of the populations studied (9 of 32) were
pure by the MRD approach, highlighting the need to rigorously
control for tumor cell contamination when searching for
infrequent variant alleles in normal cell fractions. Lastly, our
results emphasize the value of utilizing a calibrated sequencing
and sample-speciﬁc statistical approach for precise detection of
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mutations in minor cell populations during the course of CLL
evolution.
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Biological and prognostic impact of APOBEC-induced
mutations in the spectrum of plasma cell dyscrasias and
multiple myeloma cell lines
Leukemia (2018) 32, 1043–1047; doi:10.1038/leu.2017.345
Tumors are characterized by variable numbers of somatic variants
that have accumulated during the life history of the cancer cell as
a result of abnormal DNA replication and/or DNA repair processes.
The classiﬁcation of such variants into six types based on the
nucleotide change was used in the past to differentiate the crude
mutation pattern of different cancers.1 Recently, the 5′- and 3′context of each substitution was included in such analyses,

expanding the combinations to 96 possible mutation types. This
trinucleotide mutational model represents the combined effect of
several mutational signatures, and has enough resolution to allow
deconvolution of the underlying mutational processes through
the non-negative matrix factorization (NNMF) algorithm.2 To date,
more than 30 distinct signatures have been identiﬁed, opening
the ﬁeld to the investigation of the biological processes
responsible for shaping the genome of cancer, and allowing a
deeper understanding of their relative contribution in different
cancer types.2,3
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